Therapeutic plasma exchange in neurology: 2012

被引：30

作者：

Cortese, Irene ^{[1
]}

Cornblath, David R. ^{[2
]}

机构：

[1] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA

[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

来源：

JOURNAL OF CLINICAL APHERESIS | 2013年 / 28卷 / 01期

关键词：

apheresis; neurologic indications; plasmapheresis; therapeutic plasma exchange; Guillain-Barre syndrome; CIDP; myasthenia gravis; MYASTHENIA-GRAVIS; MEDICAL PROGRESS; PLASMAPHERESIS; MUSK;

D O I：

10.1002/jca.21266

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

In treating neuroimmunological diseases, neurologists have a number of different drugs to choose from ranging from corticosteroids to IVIg to more specific cell based therapies, the latter most frequently from the world of oncology. In some diseases, therapeutic plasma exchange, a procedure rather than a drug, is used. The most obvious advantage of therapeutic plasma exchange is the usually rapid onset of action presumably due to removal of pathogenic auto-antibodies. In some diseases, a single course of therapeutic plasma exchange is used while in others prolonged treatment with therapeutic plasma exchange is used. This article will review the use of therapeutic plasma exchange in neurology and will draw heavily upon recent consensus statements from the American Society for Apheresis and the American Academy of Neurology and by Cochrane reviews. J. Clin. Apheresis 28:1619, 2013. (c) 2013 Wiley Periodicals, Inc.

引用

页码：16 / 19

页数：4

共 25 条

[1]

Allen D, 2007, COCHRANE DB SYST REV, V1

[2]

[Anonymous], COCHRANE DATABASE SY

[3]

[Anonymous], 2002, COCHRANE DATABASE SY

[4]

Cornblath DR, 1996, NEUROLOGY, V47, P840

[5]

Evidence-based guideline update: Plasmapheresis in neurologic disorders Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology [J].

Cortese, I. ;

Chaudhry, V. ;

So, Y. T. ;

Cantor, F. ;

Cornblath, D. R. ;

Rae-Grant, A. .

NEUROLOGY, 2011, 76 (03) :294-300

[6]

PLASMAPHERESIS AND IMMUNOSUPPRESSIVE DRUG-THERAPY IN MYASTHENIA-GRAVIS [J].

DAU, PC ;

LINDSTROM, JM ;

CASSEL, CK ;

DENYS, EH ;

SHEV, EE ;

SPITLER, LE .

NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (21) :1134-1140

[7]

ANTI-MuSK ANTIBODY MYASTHENIA GRAVIS: CLINICAL FINDINGS AND RESPONSE TO TREATMENT IN TWO LARGE COHORTS [J].

Guptill, Jeffrey T. ;

Sanders, Donald B. ;

Evoli, Amelia .

MUSCLE & NERVE, 2011, 44 (01) :36-40

[8]

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision [J].

Hadden, Robert D. M. ;

Nobile-Orazio, Eduardo ;

Sommer, Claudia L. ;

Hahn, Angelika F. ;

Illa, Isabel ;

Morra, Enrica ;

Pollard, John D. ;

Lunn, Michael P. T. ;

Bouche, Pierre ;

Cornblath, David R. ;

Evers, Eileen ;

Koski, Carol Lee ;

Legar, Jean-Marc ;

van den Bergh, Peter ;

van Doorn, Pieter A. ;

van Schaik, Ivo N. .

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (03) :185-195

[9]

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies [J].

Hoch, W ;

McConville, J ;

Helms, S ;

Newsom-Davis, J ;

Melms, A ;

Vincent, A .

NATURE MEDICINE, 2001, 7 (03) :365-368

[10]

Intravenous immunoglobulin for Guillain-Barre syndrome [J].

Hughes, Richard A. C. ;

Swan, Anthony V. ;

van Doorn, Pieter A. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (07)

← 1 2 3 →